Abstract
Objective: To observe the clinical therapeutic effect of Shenmai Injection (SMI) in treating patients of congestive heart failure.Methods: Effect of 16 cases treated with either SMI or potassium magnesium aspartate was observed by randomized crossover method and compared.Results: By using SMI for 2 weeks, the patients’ left ventricular ejective fraction (LVEF) was increased from 29.5 ± 9.0 to 36.6 ± 10.2 (P < 0.05), the heart function of 68.75% patients was improved, no side effect or toxicity was observed. Potassium magnesium aspartate improved the heart function in 37. 50% patients only but showed no effect on LVEF.Conclusion: SMI is an effective and safe drug in treating patients with congestive heart failure.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
